康莱特注射液联合GP方案治疗晚期非小细胞肺癌的临床观察

Clinical Observation on the Therapeutic Effect of Kanglaite Injection plus GP on Advanced Non-Small Cell Lung Cancer

目的观察康莱特注射液联合GP方案治疗晚期非小细胞肺癌的临床疗效及安全性。方法将2009年3月～2012年1月在我院肿瘤内科治疗的98例晚期非小细胞肺癌患者随机分成两组,其中49人为治疗组,接受康莱特注射液和GP方案治疗,49人为对照组,仅采用GP方案治疗,比较两组治疗后的近期疗效、KPS及不良反应的发生情况。结果两组治疗总有效率分别为40.81%和30.61%,差异无统计学意义(P>0.05);治疗组的KPS改善率显著高于对照组(分别为61.22%和44.90%),差异有统计学意义(P<0.05);治疗组骨髓抑制、末梢神经炎以及脱发的发生率均显著低于对照组,差异有统计学意义(P<0.05);两组胃肠道反应及肝肾功能损害发生率相比较,差异无统计学意义(P>0.05)。结论康莱特注射液联合GP方案治疗晚期非小细胞肺癌的临床疗效略优于单纯应用GP方案,且不良反应显著减少。

Objective To explore the clinical efcacy and safety of Kangai injection combined with GP on advanced non-small cell lung cancer. Methods 98 patients with advanced non-small cell lung cancer admitted in the department of medical oncology in our hospital from March 2009 to January 20]2 were randomly divided into the treatment group（49 cases） and control group（49 cases）. The treatment group was treated with Kangai injection plus GP; the control group was treated with GP. Compared the short-term effect, KPS and toxic reaction between the two groups. Results The total effective rates of treatment group and control group were respectively 40.81% and 30.61%, and no significant difference was found（P〉0.05）; The recovery rate of treatment group was significantly higher than that of the control group（respectively 61.22 % and 44.90%, P〈0.05）. The incidence rate of bone marrow suppression, peripheral polyneuritis and alopecia were all significantly lower than those in the control group（P〈0.05）, but no significant difference in incidence rate of gastrointestinal adverse reactions and abnormal liver and renal functions was found between the two groups（P〉 0.05）. Conclusion The clinical efficacy of the Kangai injection combined with GP was a little better than GP alone for the treatment of advanced non-small cell lung cancer, and the adverse reactions significantly reduced.